Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

Koç University Transplant Immunology Research Center – Open Position

September 10, 2020

Invite to Register Details in African Scientists Directory

July 24, 2020

IUIS Anti-Racism Statement

July 16, 2020

Share Immunology with your family and friends!

July 7, 2020

Global Science TV – Participate in the Public Value of Science project

June 29, 2020

African Scientists Directory

June 29, 2020

We have a winner! 2020 Early Career Research Prize in Vaccinology R&D

May 18, 2020Vaccine Committee (VAC)

2020 Edition: Day of Immunology

April 30, 2020

Menarini Prize for Outstanding Woman Immunologist

April 29, 2020Gender Equality Committee (GEC)